冠状动脉旁路移植术后最佳抗血小板策略:一项荟萃分析
DAPT较SAPT降低全因死亡、心血管死亡和MACCE,但增加大出血和小出血;DAPT-T/P较DAPT-C降低全因和心血管死亡,其他结局无差异。
要点
- CABG术后DAPT较SAPT降低全因死亡、心血管死亡和MACCE,但增加大出血和小出血风险。
- DAPT-T/P较DAPT-C降低全因死亡和心血管死亡,其他心血管或出血结局无显著差异。
- 需根据缺血和出血风险个体化选择CABG术后抗血小板方案。
核心结论
- CABG术后DAPT较SAPT降低全因死亡、心血管死亡和MACCE,但增加大出血和小出血。
- DAPT-T/P较DAPT-C降低全因死亡和心血管死亡,其他心血管或出血结局无差异。
- 需基于缺血和出血风险个体化选择抗血小板方案。
研究设计与样本
- 遵循PRISMA指南的系统综述与荟萃分析。
- 检索PubMed、Ovid Medline、Ovid Embase和Cochrane Central Register of Controlled Trials。
主要发现
- DAPT vs SAPT:全因死亡OR 0.65(95%CI 0.50-0.86;p=0.002),心血管死亡OR 0.53(95%CI 0.33-0.84;p=0.008),MACCE OR 0.68(95%CI 0.51-0.91;p=0.01)。
- DAPT vs SAPT:大出血OR 1.30(95%CI 1.08-1.56;p=0.007),小出血OR 1.87(95%CI 1.28-2.74;p=0.001)。
- DAPT-T/P vs DAPT-C:全因死亡OR 0.43(95%CI 0.29-0.65;p≤0.0001),心血管死亡OR 0.44(95%CI 0.24-0.80;p=0.008)。
- DAPT-T/P vs DAPT-C:其他心血管或出血结局无差异。
关键数值与推荐
- DAPT较SAPT显著降低全因死亡(OR 0.65,95%CI 0.50-0.86;p=0.002)。
- DAPT较SAPT显著增加大出血(OR 1.30,95%CI 1.08-1.56;p=0.007)和小出血(OR 1.87,95%CI 1.28-2.74;p=0.001)。
- DAPT-T/P较DAPT-C显著降低全因死亡(OR 0.43,95%CI 0.29-0.65;p≤0.0001)和心血管死亡(OR 0.44,95%CI 0.24-0.80;p=0.008)。
临床怎么用
- CABG术后选择DAPT需权衡缺血获益与出血风险,尤其关注大出血和小出血增加。
- 在DAPT基础上,优先选用替格瑞洛或普拉格雷可能较氯吡格雷降低全因和心血管死亡。
- 对急性冠脉综合征患者,DAPT的死亡获益可能更明显,应个体化决策。
局限性
- 原文未报告纳入研究的偏倚风险、异质性或敏感性分析结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Coronary artery bypass grafting (CABG) is an established revascularisation strategy for multivessel and left main coronary artery disease. Although aspirin is routinely recommended for patients with CABG, the optimal antiplatelet regimen after CABG remains unclear. We evaluated the efficacies and risks of different antiplatelet regimens (dual (DAPT) versus single (SAPT), and dual with clopidogrel (DAPT-C) versus dual with ticagrelor or prasugrel (DAPT-T/P)) after CABG. METHODS: We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and performed a comprehensive literature search using PubMed, Ovid Medline, Ovid Embase and Cochrane Central Register of Controlled Trials. Data were extracted and pooled using random-effects models and Review Manager (V.5.4). RESULTS: Among the 2970 article abstracts screened, 215 full-text articles were reviewed and 38 studies totaling 77 447 CABG patients were included for analyses. DAPT compared with SAPT was associated with significantly lower all-cause mortality (OR 0.65 with 95% CI 0.50 to 0.86; p=0.002), cardiovascular mortality (OR 0.53, 95% CI 0.33 to 0.84; p=0.008), and major adverse cardiac and cerebrovascular events (MACCE) (OR 0.68, 95% CI 0.51 to 0.91; p=0.01), but higher rates of major (OR 1.30, 95% CI 1.08 to 1.56; p=0.007) and minor bleeding (OR 1.87, 95% CI 1.28 to 2.74; p=0.001) after CABG. DAPT-T/P compared with DAPT-C was associated with significantly lower all-cause (OR 0.43, 95% CI 0.29 to 0.65; p≤0.0001) and cardiovascular mortality (OR 0.44, 95% CI 0.24 to 0.80; p=0.008), and no differences on other cardiovascular or bleeding outcomes after CABG. CONCLUSION: In patients with CABG, DAPT compared with SAPT and DAPT-T/P compared with DAPT-C were associated with reduction in all-cause and cardiovascular mortality, especially in patients with acute coronary syndrome. Additionally, DAPT was associated with reduction in MACCE, but higher rates of major and minor bleeding. An individualised approach to choosing antiplatelet regimen is necessary for patients with CABG based on ischaemic and bleeding risks.
引用
- Agrawal, Kumar, Majid, et al. Optimal antiplatelet strategy following coronary artery bypass grafting: a meta-analysis. Heart. 2024. PMID: 37648436. doi:10.1136/heartjnl-2023-323097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。